Distinct Single Cell Gene Expression in Peripheral Blood Monocytes Correlates With Tumor Necrosis Factor Inhibitor Treatment Response Groups Defined by Type I Interferon in Rheumatoid Arthritis

Previously, we demonstrated in test and validation cohorts that type I IFN (T1IFN) activity can predict non-response to tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA). In this study, we examine the biology of non-classical and classical monocytes from RA patients defined by their pre-biologic treatment T1IFN activity. We compared single cell gene expression in purified classical (CL, n = 342) and non-classical (NC, n = 359) monocytes. In our previous work, RA patients who had either high IFNβ/α activity (>1.3) or undetectable T1IFN were likely to have EULAR non-response to TNFi. In this study comparisons were made among patients grouped according to their pre-biologic treatment T1IFN activity as clinically relevant: “T1IFN undetectable (T1IFN ND) or IFNβ/α >1.3” (n = 9) and “T1IFN detectable but IFNβ/α ≤ 1.3” (n = 6). In addition, comparisons were made among patients grouped according to their T1IFN activity itself: “T1IFN ND,” “T1IFN detected and IFNβ/α ≤ 1.3,” and “IFNβ/α >1.3.” Major differences in gene expression were apparent in principal component and unsupervised cluster analyses. CL monocytes from the T1IFN ND or IFNβ/α >1.3 group were unlikely to express JAK1 and IFI27 (p < 0.0001 and p 0.0005, respectively). In NC monocytes from the same group, expression of IFNAR1, IRF1, TNFA, TLR4 (p ≤ 0.0001 for each) and others was enriched. Interestingly, JAK1 expression was absent in CL and NC monocytes from nine patients. This pattern most strongly associated with the IFNβ/α>1.3 group. Differences in gene expression in monocytes among the groups suggest differential IFN pathway activation in RA patients who are either likely to respond or to have no response to TNFi. Additional transcripts enriched in NC cells of those in the T1IFN ND and IFNβ/α >1.3 groups included MYD88, CD86, IRF1, and IL8. This work could suggest key pathways active in biologically defined groups of patients, and potential therapeutic strategies for those patients unlikely to respond to TNFi.

[1]  Wei Wang,et al.  Joint Location–Specific JAK‐STAT Signaling in Rheumatoid Arthritis Fibroblast‐like Synoviocytes , 2019, ACR open rheumatology.

[2]  Jörg Menche,et al.  Non-classical monocytes as mediators of tissue destruction in arthritis , 2018, Annals of the rheumatic diseases.

[3]  D. Foell,et al.  Treating juvenile idiopathic arthritis to target: recommendations of an international task force , 2018, Annals of the rheumatic diseases.

[4]  T. Niewold,et al.  Type I interferon in rheumatic diseases , 2018, Nature Reviews Rheumatology.

[5]  M. Lunt,et al.  Twenty‐Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register , 2017, Arthritis & rheumatology.

[6]  Amit A. Patel,et al.  The fate and lifespan of human monocyte subsets in steady state and systemic inflammation , 2017, The Journal of experimental medicine.

[7]  M. Jensen,et al.  Single-cell gene expression patterns in lupus monocytes independently indicate disease activity, interferon and therapy , 2017, Lupus Science & Medicine.

[8]  T. Takeuchi,et al.  CD14brightCD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis , 2017, Arthritis Research & Therapy.

[9]  P. Gregersen,et al.  Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. , 2016, Annals of the rheumatic diseases.

[10]  Radu Dobrin,et al.  Integrative genomic deconvolution of rheumatoid arthritis GWAS loci into gene and cell type associations , 2016, Genome Biology.

[11]  T. Niewold,et al.  The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases. , 2016, Gene.

[12]  M. Rossol,et al.  Brief Report: Autocrine Cytokine–Mediated Deficiency of TRAIL‐Induced Monocyte Apoptosis in Rheumatoid Arthritis , 2015, Arthritis & rheumatology.

[13]  Shruti Sharma,et al.  Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. , 2015, Journal of autoimmunity.

[14]  Evan Z. Macosko,et al.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets , 2015, Cell.

[15]  G. Barton,et al.  MyD88: a central player in innate immune signaling , 2014, F1000prime reports.

[16]  G. Haines,et al.  Nonclassical Ly6C(-) monocytes drive the development of inflammatory arthritis in mice. , 2014, Cell reports.

[17]  A. Skol,et al.  Genetic Analysis of the Pathogenic Molecular Sub-phenotype Interferon Alpha Identifies Multiple Novel Loci Involved in Systemic Lupus Erythematosus , 2014, Genes and Immunity.

[18]  M. Rauh,et al.  T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway , 2014, Science Translational Medicine.

[19]  L. Ivashkiv,et al.  Regulation of type I interferon responses , 2013, Nature Reviews Immunology.

[20]  T. Beddoe,et al.  Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1 , 2013, Nature Immunology.

[21]  F. Miot,et al.  IFNβ/TNFα synergism induces a non-canonical STAT2/IRF9-dependent pathway triggering a novel DUOX2 NADPH Oxidase-mediated airway antiviral response , 2013, Cell Research.

[22]  J. Kay,et al.  Evolution of treatment for rheumatoid arthritis. , 2012, Rheumatology.

[23]  H. Takayanagi.  New developments in osteoimmunology , 2012, Nature Reviews Rheumatology.

[24]  A. Reder,et al.  Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. , 2012, Archives of neurology.

[25]  P. Hertzog,et al.  MyD88 Drives the IFN-β Response to Lactobacillus acidophilus in Dendritic Cells through a Mechanism Involving IRF1, IRF3, and IRF7 , 2012, The Journal of Immunology.

[26]  G. Firestein,et al.  The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon , 2011, Annals of the rheumatic diseases.

[27]  D. Walker,et al.  Quantifying the economic burden of productivity loss in rheumatoid arthritis. , 2011, Rheumatology.

[28]  T. Niewold,et al.  Familial Aggregation of Autoimmune Disease in Juvenile Dermatomyositis , 2011, Pediatrics.

[29]  J. Harley,et al.  Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[30]  A. Boonen.  Faculty Opinions recommendation of Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. , 2010 .

[31]  A. Woolf,et al.  Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study , 2010, Arthritis research & therapy.

[32]  Maurizio Cutolo,et al.  Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.

[33]  L. Ivashkiv,et al.  TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon–response genes , 2008, Nature Immunology.

[34]  J. Buyon,et al.  Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. , 2008, Arthritis and rheumatism.

[35]  J. Harley,et al.  High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus , 2007, Genes and Immunity.

[36]  E. Coccia,et al.  Sensitization to TLR7 Agonist in IFN-β-Preactivated Dendritic Cells1 , 2007, The Journal of Immunology.

[37]  K. Honda,et al.  Type I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors , 2006 .

[38]  S. Gordon,et al.  Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.

[39]  D. Levy,et al.  Tissue-specific Positive Feedback Requirements for Production of Type I Interferon following Virus Infection* , 2005, Journal of Biological Chemistry.

[40]  M. Peterson,et al.  Coordinate overexpression of interferon‐α–induced genes in systemic lupus erythematosus , 2004 .

[41]  M. Boers.  Understanding the window of opportunity concept in early rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[42]  F. Otsuka,et al.  Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner. , 2002, Cytokine.

[43]  A. Ramsay,et al.  IFN-gamma regulates murine interferon-inducible T cell alpha chemokine (I-TAC) expression in dendritic cell lines and during experimental autoimmune encephalomyelitis (EAE). , 2002, Scandinavian journal of immunology.

[44]  R. Schreiber,et al.  Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses , 1998, Cell.

[45]  J. Wautier,et al.  Blood monocyte activation in rheumatoid arthritis: increased monocyte adhesiveness, integrin expression, and cytokine release , 1996, Clinical and experimental immunology.

[46]  A. Silman,et al.  The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. , 1994, British journal of rheumatology.

[47]  U. Nir,et al.  Priming affects the transcription rate of human interferon-beta 1 gene. , 1985, The Journal of biological chemistry.

[48]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[49]  M. Cross,et al.  Rheumatoid arthritis. , 2010, Best practice & research. Clinical rheumatology.

[50]  W. Cao,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 22, 2013. For personal use , 2006 .

[51]  P. Gregersen,et al.  Peripheral blood gene expression profiling in rheumatoid arthritis , 2005, Genes and Immunity.

[52]  P. Hannonen,et al.  Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. , 2005, Arthritis and rheumatism.